newsfilter
← Latest News
Business Wire·

Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia

Allowance to extend into 2036 patent claims related to method of treating patients with A-T using the company's proprietary EryDex process Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company